Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 50%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings has demonstrated a robust turnaround, evidenced by an 11.3% growth in its BoneCement and Surgical segments due to successful placements of the Rosa technology. The firm benefits from a healthy balance sheet and has consistently shown growth in line or above its peers across multiple quarters, supported by the favorable orthopedic market conditions. Additionally, the company’s knee segment exhibited a global growth rate of 5.3%, driven by innovative product offerings and increasing market penetration, which positions it well for future profitability.

Bears say

Zimmer Biomet Holdings (ZBH) faces a challenging outlook due to stagnant average selling prices (ASP) anticipated for FY25 and lowered growth estimates across revenue segments, projecting only 5.4% year-over-year growth for FY26. The company's knee and hip product lines have demonstrated weaker performance relative to peers, with significant market share risks coupled with execution challenges hindering growth. Additionally, potential delays in the commercialization of new products like ROSA and increased restructuring costs further contribute to a cautious assessment of ZBH's financial trajectory.

ZBH has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 50% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 18 analysts, ZBH has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.